The Evidence Based Rheumatology Podcast

The Evidence Based Rheumatology Podcast header image 1

E60: COVID19 Series - Hydroxychloroquine #2

March 26th, 2020

Trying to get to IL6, but so much happening in the world of hydroxychloroquine. As I said at the beginning, things are likely to move fast.  I'm planning to make this as an extended series, so please go back and listen to #1 before you listen to this!  This episode will round out the paper by Gautret et al. and discuss the best copy of a paper by Jun et al. that I've been able to find. Follow me @ebrheum and share with friends! 

E59: COVID19 Series - Hydroxychloroquine v1

March 20th, 2020

Welcome to the first episode of my series on immunosuppressive treatments for COVID-19. Today I cover the Renault trial and a nice systematic review, which I believe are the two best options in the published literature to date.  Find the papers and ways to subscribe at ebrheum.com and follow me on twitter @ebrheum

E58: Brief Update - Podcasting in the Era of COVID-19

March 19th, 2020

Quick update podcast.  I'm planning to tweak the format of my podcast to better respond to COVID-19.  I'll be doing more or less the same thing but with a different structure and focus.  It seems a little peculiar to discuss anything else during the current crisis, so I intend to refocus and hope to offer value to listeners.  Share with friends - ebrheum.com and @ebrheum

E57: PEXIVAS Trial - PLEX and Reduced Steroid in ANCA Vasculitis

February 19th, 2020

PEXIVAS has landed!  This week I go over the trial and my take on it's results.  Impressive undertaking that answered two questions for a subset of patients with AAV - well worth the time to kick back and read the trial in full. Let me know what you think about the podcast @ebrheum! 

E56: Continue or Withdraw Prednisone in SLE (CORTICOLUP)

February 6th, 2020

(Yet) another RCT this week!  Nice investigator initiated trial with many wonderful strengths and a few crippling flaws. Great opportunity to think about a common problem in practice as well as a separate common problem in trials! 

E55: Anifrolumab for SLE (TULIP 1&2)

January 23rd, 2020

This week I talk about the recently published TULIP 1 and TULIP 2 trials that assessed anifrolumab for active SLE.  Great to see a new drug in this disease state; interesting to think through how these trials played out.  Get the papers and the pod at ebrheum.com and follow me @ebrheum if you'd like to share feedback! 

E54: Rheum4Debate - Triple Tx is 1st Line in RA w/No Response to MTX

January 16th, 2020

Happy New Year!  This week Dr. Anisha Dua (@anisha_dua) and Dr. Sarah Fantus (@sarahfantus) debate this motion: "In MTX non-responders with RA, triple therapy (adding HCQ & SSZ) should be first line."  Please be sure to VOTE AGAIN on twitter (@ebrheum) after you have listened! 

E53: Another Look at Nintedanib for SSc-ILD

December 19th, 2019

This week I go back to a topic from episode 42, the SENSCIS trial and nintedanib for SSc-ILD.  The way this medication has been received and a recent article I wrote for The Rheumatologist gave me a nice jumping off point to cover a few more issues from this. Be sure to follow me @EBRheum to let me know what you think! The corresponding article is available here: https://www.the-rheumatologist.org/article/fda-approves-nintedanib-for-ssc-ild-but-temper-your-expectations/

E52: HOPE RCT - Prednisone for OA of the Hand

December 4th, 2019

Surprising RCT this week discussing the HOPE trial, which pitted 10mg prednisone against placebo for inflammatory hand OA. I do think this will change my practice, but in a far narrower sense than the headline would suggest. Check it out and find all my other content at ebrheum.com! 

E51: Rheum4Debate - “Start TCZ Upfront in GCA”

November 26th, 2019

Rheum4Debate is back!  This week we have Dr. Anisha Dua arguing in support of the motion, "Patients with newly diagnosed GCA should start glucocorticoids WITH tocilizumab over glucocorticoids alone."  I argue against the motion and Dr. Sarah Fantus was kind enough to moderate.  
 
In our pre-debate poll, 51% supported the motion, 34% disagree with the motion, and 15% were undecided.  Please be sure to vote in the post-debate motion on twitter as well!  Find me @ebrheum, Dr. Dua @anisha_dua, and Dr. Fantus @sarahfantus.  

Play this podcast on Podbean App